Evidence map›Paper›PMID 36137197›Full record

ArticleChemical research in toxicology2022

Shared Clavulanate and Tazobactam Antigenic Determinants Activate T-Cells from Hypersensitive Patients.

Adriana Ariza, Kanoot Jaruthamsophon, Xiaoli Meng, Marina Labella, Kareena Adair, Arun Tailor, Chonlaphat Sukasem, Paul Whitaker, Daniel Peckham, Munir Pirmohamed and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical research in toxicology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Adriana ArizaAllergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, 29009 Málaga, Spain.
Kanoot JaruthamsophonDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool L69 3GE, U.K.
Xiaoli MengDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool L69 3GE, U.K.ORCID 0000-0002-7774-2075
Marina LabellaAllergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, 29009 Málaga, Spain.
Kareena AdairDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool L69 3GE, U.K.
Arun TailorDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool L69 3GE, U.K.
Chonlaphat SukasemDivision of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
Paul WhitakerBradford Teaching Hospitals NHS Trust, Bradford BD9 6DA, U.K.
Daniel PeckhamRegional Adult Cystic Fibrosis Unit, St James's University Hospital, Leeds LS9 7TF, U.K.
Munir PirmohamedDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool L69 3GE, U.K.
María José TorresAllergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, 29009 Málaga, Spain.
Dean John NaisbittDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool L69 3GE, U.K.ORCID 0000-0003-4107-7832
University of Liverpool · GBHospital Regional Universitario de Málaga · ESBradford Teaching Hospitals NHS Foundation Trust · GBInstituto de Investigación Biomédica de Málaga · ESMahidol University · THSt James's University Hospital · GB

Funding

Medical Research Council MR/L006758/1Medical Research Council MR/R009635/1
6 · The paper itself

Abstract

β-Lactamase inhibitors such as clavulanic acid and tazobactam were developed to overcome β-lactam antibiotic resistance. Hypersensitivity reactions to these drugs have not been studied in detail, and the antigenic determinants that activate T-cells have not been defined. The objectives of this study were to (i) characterize clavulanate- and tazobactam-responsive T-cells from hypersensitive patients, (ii) explore clavulanate and tazobactam T-cell crossreactivity, and (iii) define the antigenic determinants that contribute to T-cell reactivity. Antigen specificity, pathways of T-cell activation, and crossreactivity with clavulanate- and tazobactam-specific T-cell clones were assessed by proliferation and cytokine release assays. Antigenic determinants were analyzed by mass spectrometry-based proteomics methods. Clavulanate- and tazobactam-responsive CD4

Indexed as

beta-Lactamase InhibitorsT-LymphocytesAldehydesAnti-Bacterial AgentsClavulanic AcidEpitopesHumansTazobactamAldehydesAnti-Bacterial Agentsbeta-Lactamase InhibitorsClavulanic AcidEpitopesTazobactam

Identifiers

PMID36137197
PMCPMC9682523
OpenAlexW4296803219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.